Document is current
Any future updates will be listed below
-
Authors
Masramon, Marta https://orcid.org/0009-0006-3129-8948
Mathew, Manju
Singh, Saurabh
Mertzanidou, Thomy
Clemente, Joey
Retter, Adam
Thorley, Natasha
Phipps, Adam
Parry, Thomas
Papoutsaki, Marianti-Vasiliki
Smith, Lorna
Grussu, Francesco
Kasivisvanathan, Veeru
Grey, Alistair
Dinneen, Eoin
Shaw, Greg
Patel, Dominic
Caselton, Lucy
Moore, Caroline M.
Atkinson, David
Haider, Aiman
Freeman, Alex
Alexander, Daniel C.
Punwani, Shonit
Panagiotaki, Eleftheria
-
Funding
Funding for this research was provided by:
Engineering and Physical Sciences Research Council (EP/S021930/1)
Engineering and Physical Sciences Research Council (EP/N021967/1)
Engineering and Physical Sciences Research Council (EP/R006032/1)
Prostate Cancer UK (PG14-018-TR2)
UCLH Biomedical Research Centre
Cancer Research UK
- License Information
-
More Information
Article History
Received: 19 February 2026
Revised: 15 July 2026
Accepted: 5 August 2026
First Online: 9 September 2026
Declarations
Ethics approval and consent to participate: Ethical approval for this prospective study was granted by the London-Queen Square Research Ethics Committee (19/LO/1803) on 23 January 2020. All screened participants were provided with Participant Information Leaflets detailing the study's objectives and their involvement; those interested provided informed written consent.
Consent for publication: Not applicable.
Competing interests: The authors of this manuscript declare relationships with the following companies: Qubim (SP), NVision (SP), Gold Standard Phantoms (SP), Angle plc. (GS), Sonablate (AG), AngioDynamics (AG), HC21/Aquilant (AG), Docus AI (SS), and Queen Square Analytics (DA).
